Aratana Therapeutics (PETX) Reports In-Line Q1 EPS

Aratana Therapeutics (NASDAQ: PETX) reported Q1 EPS of ($0.34), in-line with the analyst estimate of ($0.34). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $3.07 million.

For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• CalPrivate Bank names Andra Frazier as chief credit officer
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance